HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DEA cut from Prop 65

This article was originally published in The Rose Sheet

Executive Summary

Diethanolamine will not be listed under Prop 65, California's Office of Environmental Health Hazard Assessment announces March 7. Based upon public comments, OEHHA concludes "it is not clear that the scientific criteria for listing under the authoritative bodies have been met." Office determined sufficient criteria to propose listing the ingredient in 1999 despite attempts by the Cosmetic, Toiletry & Fragrance Association to oppose the listing. Decision coincides with recent recommendation by National Toxicology Program Board of Scientific Counselors subcommittee not to include DEA in NTP's upcoming 11th Report on Carcinogens (1"The Rose Sheet" Nov. 25, 2002, p. 5)...

You may also be interested in...

DEA Exclusion From 11th Report On Carcinogens Advised By NTP Panel

Existing data suggesting diethanolamine may pose a safety risk do not meet National Toxicology Program criteria to be designated a possible human carcinogen, an NTP Board of Scientific Counselors subcommittee concluded at a meeting in Bethesda, Md. Nov. 19

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts